Shanghai tech board unlikely to challenge Hong Kong’s status as preferred IPO hub for Chinese biotech firms

Investment bankers say US-China trade war may dampen valuations of biotech firm IPOs in Hong Kong, but overall numbers likely to remain intact While Chinese biotech companies are likely to opt for …
( read original story …)

---